Fig. 1.

Study overview of pre-clinical, clinical and omics studies using high-dose VitC as anti-cancer agent. Estimated bar graphs of most represented cancer types VitC doses are shown in orange and include high dose (≥ 1 mM in vitro or 1 g/kg in vivo and clinical), medium dose (≤ 0.5 mM in vitro), and low dose (≤ 0.1 mM in vitro,< 1 g/kg in vivo, ≤ 10 g whole body dose clinical). Less represented tumour types are further described in Tables 1, 2, 3 and 4, where oral doses are also included if applicable. Described effect in pre-clinical studies is expressed by percentage of the total number of studies. Reported results in completed clinical trials are expressed by number of studies. Number of studies per global molecular profiling type are also indicated. Omic results include n = 20 in vitro and n = 4 in vivo studies